ABSTRACT
Purpose To test whether continuous hypoxia is neuroprotective to retinal ganglion cells (RGCs) in a mouse model of mitochondrial optic neuropathy.
Methods RGC degeneration was assessed in genetically modified mice in which the floxed gene for the complex I subunit NDUFS4 is deleted from RGCs using Vlgut2-driven Cre recombinase. Beginning at postnatal day 25 (P25), Vglut2-Cre;ndufs4loxP/loxP mice and control littermates were housed under hypoxia (11% oxygen) or were kept under normoxia (21% oxygen). Survival of RGC somas and axons was assessed at P60 and P90 via histological analysis of retinal flat mounts and optic nerve cross sections, respectively. Retinal tissue was also assessed for neuroinflammation using Western blot and confocal microscopy.
Results Consistent with our previous characterization of this model, at least one-third of RGCs had degenerated by P60 in Vglut2-Cre;ndufs4loxP/loxP mice remaining under normoxia. However, continuous hypoxia resulted in complete rescue of RGC somas and axons at this time point, with normal axonal myelination observed on electron microscopy. Though only partial, hypoxia-mediated rescue of complex I-deficient RGC somas and axons remained significant at P90. Hypoxia prevented reactive gliosis at P60, while the retinal accumulation of Iba1-positive mononuclear inflammatory cells was not substantially reduced.
Conclusions Continuous hypoxia achieved dramatic rescue of early RGC degeneration in mice with severe mitochondrial dysfunction. Although complete rescue was not durable to P90, our observations suggest that investigating the mechanisms underlying hypoxia-mediated neuroprotection of RGCs may identify useful therapeutic strategies for optic neuropathies resulting from less profound mitochondrial impairment, such as Leber Hereditary Optic Neuropathy.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
The authors declare no conflict of interest.
This work was funded by the National Eye Institute via grants EY028610 (S.M.G.), and Core Grant EY005722 (Duke University), a Duke University School of Medicine Strong Start Award (S.M.G.), a Career Development Award from Research to Prevent Blindness (S.M.G.) and an Unrestricted Research to Prevent Blindness Grant (Duke Eye Center).